Our group puts its focus on biomarker-assisted, in particular Alzheimer’s disease (AD). We are especially interested in cerebrospinal fluid biomarkers. We have gained expertise in analyzing cerebrospinal fluid for established biomarkers as Tau and Abeta. Furthermore we aim to establish new biomarkers for a more specific diagnosis of neurodegenerative diseases. We also have a focus on discriminating AD from mood disorders like depression.

We are specialized in conducting interventional clinical trials in cooperation with the pharmaceutical industry as well as observational clinical trials like DELCODE and DESCRIBE-FTD.

Among others, we are associated with the Berlin Institute of Health (BIH), the Max-Delbrück-Centre (MDC) and the European Alzheimer’s Disease Consortium (EADC).

Beside this, our research group is also involved in the development of health care research. Therefore, we are participating in several gerontological research projects with the focus on dementia.

In our health care research unit it is our aim to improve and stabilize the situation for people with dementia and their caregivers in home dementia care for as long as possible. We focus on the potential of assistive technologies. Our previous user studies dealing in various stages of development with the acceptance, usability and feasibility of technical devices in everyday life. The aim is to develop and evaluate new assistive technologies that can provide relief for people with dementia and their caregivers.